Highlights
1 patent
About
Nanorobots for Targeting and Destroying Cancer Cells
Nanorobotics is a preclinical-stage startup on a mission to eradicate cancer by harnessing the power of its breakthrough, patented light-activated nanomolecular platform technology.
Nanorobotics platforms leverage the unique characteristics of a Molecular Nanomachines (MNMs), which can drill mechanically through the cell membrane, to develop a pipeline of safe and effective molecular therapies for treating cancers that have shown resistance to conventional therapies.
Nanorobotics leading molecule, MNM96, exhibits an excellent preclinical efficacy and safety profile and is well positioned to advance toward the first human clinical trials in 2025.
Identity
| Name | Nanorobotics |
|---|---|
| Slug | nanorobotics |
| Type / kind | startup |
| Crunchbase ID | nanorobotics |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4KHl59gKDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Nov 2024 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Hod HaSharon |
| HQ address | HaNagar St 24, Hod Hasharon, Israel |
Web & social
| https://www.linkedin.com/company/65689400 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business models
B2B
Tags
pharmaceuticalscancer-therapyoncologytreatmentstargeted-therapybiotechnologycell-therapynanotechnology
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}